The acquisition will integrate advanced MRD testing into a leading AI oncology platform, expanding market reach and accelerating test volume growth. The $1.7B deal, expected to close in Q4 2026, aims to drive revenue and data synergies while enhancing competitive positioning.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.